Trump wins U.S. election | Expert analysis on e-cigarette policy direction under the next administration

Nov.06.2024
Trump wins U.S. election | Expert analysis on e-cigarette policy direction under the next administration
Tom Beaudet, CEO of U.S. compliance firm Accorto, reviewed the effectiveness of past bipartisan policies and predicts that the FDA will improve its review process, allowing e-cigarette products to gain market approval more quickly in the future.

The results of the 2024 U.S. presidential election have been revealed, with Donald Trump elected as the new president. As the largest e-cigarette market in the world, the direction and regulatory policies of the U.S. market have significant global implications. How the new administration will regulate e-cigarettes and the future of the U.S. e-cigarette market are questions drawing global industry attention. As a leading global vaping technology media and think tank, 2Firsts quickly connected with U.S. compliance experts to provide the most authoritative analysis.

 

Tom Beaudet, CEO of U.S. compliance firm Accorto, shared with 2Firsts his thoughts on the regulatory approaches and actions of both the Trump administration and the current Democratic government on e-cigarettes. He emphasized that, during the current administration's four years, only 9 harm-reduction product applications were approved, despite millions of applications being submitted. He predicts that under the next administration, the FDA may gradually establish a clearer market entry pathway, helping companies that submit complete scientific data gain market access more quickly.

 

Trump wins U.S. election | Expert analysis on e-cigarette policy direction under the next administration
Accorto CEO Tom Beaudet | Image source: 2Firsts

 

Read the full perspective from Tom Beaudet:

 

  • Several weeks ago, ex President Donald Trump made the statement that he saved flavored vapes in 2020 and that, if he is elected again, he will save flavors again. However, it must be remembered that flavored closed pod systems were banned during the Trump presidency.

 

  • During the past 4 years, FDA has only approved 9 new harm reduction products, although applications have been submitted for millions of new products.  Although the vast majority of those applications were not complete with the scientific data needed for substantive review by the CTP Office of Science, several companies did submit high quality applications and are still awaiting a final decision.  Many question why we should expect anything different under another Democratic Party administration.

 

  • There is hope, regardless of who walks away victorious on November 5.  The US VTA, led by their president Tony Abud, has been aggressively working to educate members of Congress from both parties about the life saving potential of Nicotine Harm Reduction products and the importance of making changes at FDA to repair the currently broken review process.  Regardless of who wins tomorrow, we should expect to see improvements in the PMTA review process where applications who spend the money and time to submit high quality applications have a known and proven pathway to a Market Granted Order.  As more products are approved and we develop a pool of predicate products to reference, the known pathway to success will be come more and more established.

 


 

2Firsts will continue to bring the latest reports and interpretations on U.S. e-cigarette policies.

 

Disclaimer: This article represents only the views of the expert.

AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Limited, a wholly owned subsidiary of AIR Global, has launched an offering of U.S. dollar-denominated senior unsecured notes, with proceeds primarily intended to repay its existing term loan and revolving credit facility. AIR has not disclosed the final size, maturity or coupon; Refinitiv, citing Moody's, reported an expected issuance of approximately $400 million and a Ba3 rating. AIR had about $412.4 million outstanding under the two bank facilities at June 30 and net debt of $344.8 million. In the first half of 2026, AIR's Al Fakher-led flavored shisha molasses business generated about 99% of company revenue, while New Growth Categories including Crown Switch produced $2.2 million in revenue and remained loss-making on an adjusted EBITDA basis.
Sep.23
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24
2Firsts Hosts U.S. Market Mid-Year Briefing: Companies Need to Reassess Product and Market-Access Strategies
2Firsts Hosts U.S. Market Mid-Year Briefing: Companies Need to Reassess Product and Market-Access Strategies
2Firsts held its 2026 U.S. Market Compliance and Development Mid-Year Briefing in Shenzhen, China, on July 28. The discussion examined how state-level requirements, proposed foreign-establishment registration rules and expanding supply-chain responsibilities are changing product and investment decisions in the U.S. tobacco and nicotine market.
Jul.29
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
A new expert paper in JAMA urges U.S. clinicians to include nicotine e-cigarettes in smoking-cessation discussions, citing higher quit rates than nicotine replacement therapy. It also stresses that products must deliver enough nicotine to replace cigarettes, dual use should be brief, and complete switching is the goal. 2Firsts argues the recommendations matter beyond clinics: public-health professionals should reassess relative risk, regulators should preserve sufficient product appeal for adult smokers, and manufacturers should focus on helping users quit cigarettes more sustainably.
SCIENCE
Aug.03 by 2Firsts Perspectives
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10